19 June 2013
Keywords: osi, tarceva, earns, 0m, 4th-qtr, usa, pharmaceuticals
Article | 13 February 2006
The USA's OSI Pharmaceuticals says that international sales of its flagship product Tarceva (erlotinib) were $25.0 million for the fourth
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 February 2006
© 2013 thepharmaletter.com